Navigation Links
Jaw Reconstruction could be Possible in Oral Cancer Patients

Mayo Clinic ENT pioneers have found a new method to reform the mandible (lower jaw) of oral cancer patients// .

Senior investigator of the study, Eric Moore, M.D., said that without reconstructive procedures difficulties such as in eating, speaking and facial abnormalities would be seen in mandible-removed oral cancer patients.

‘We think this new process can be a huge advantage for patients and a good tool for reconstructive surgeons,’ says Daniel Price, M.D., Mayo Clinic ear, nose and throat surgery resident and lead study investigator. ‘We're excited about it. It will not completely replace the current mandible reconstruction method -- transfer of bone -- but down the road, I think that this method of reconstruction will be done regularly in patients with cancer involving the mandible.’

Patients who might be candidates for the new reconstructive and treatment procedure have oral cancer involving part of the mandible. To completely remove the tumor surgically, surgeons have to remove part of the mandible. Without reconstructive surgery, patients would have difficulty eating and speaking, and would develop a significant facial deformity, says Eric Moore, M.D., Mayo Clinic ear, nose and throat surgeon and senior study investigator.

The new method, which the investigators tested in rabbits, used distraction osteogenesis after tumor removal surgery to restore the missing portion of a patient's jaw. With distraction osteogenesis, the surgeon made a cut at one of the remaining ends of the patient's jawbone. As the break healed, the first phase of growth, soft tissue, appeared. The surgeon then stretched the pliable soft tissue under the tension of a device to fill in the gap in the patient's jaw. Within 24 hours of completing the stretching process, physicians started administering radiation therapy to the mandible to decrease the likelihood of cancer recurrence. As the soft tissue healed, it hardened into bone. The investigators
'"/>




Page: 1 2 3

Related medicine news :

1. Cancers & Reconstruction
2. Radiation after Breast Reconstruction
3. A New Bioactive Cement For Facial Reconstruction the future
4. Tissue Engineering for Craniofacial Reconstruction
5. Virus Level could Predict Cervical Cancer Risk
6. Beware of the oral patch! It could be cancer!!!
7. Prozac miracle could end in disaster
8. Wonder drug - could end in disaster
9. Pollution could be a risk
10. Fright could be more harmful
11. Pregnant smokers could harm their child
Post Your Comments:
(Date:8/29/2008)...ton Scientific obligation reduced from $250 to $19...tCall/ -- Boston Scientific,Corporation (NYSE: BS...f,Marshall, Texas found two patents of Medtronic, ...onduct during the prosecution of the patents,befor... A jury had previously found that certain Boston S...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin... the Hispanic community is benefiting. , ... 2008 -- Dr. Milton Owens and the Coastal Center f...fornia to provide protection for cash paying patie...
(Date:8/29/2008)... Trusted life science software prov...lients to engage via GSA. , ...ions, an emerging software engineering firm dedic...a U.S. General Services Administration (GSA) Contr...stomers with the ability to conveniently engage 5A...
(Date:8/28/2008)...enues increase 138% versus Q2 2007 - Nine new C.../PRNewswire-FirstCall/ - CRH Medical Corporation,(...he three and six months,ended June 30, 2008 (all f...onths ended June 30, 2008 increased 138% to $1,653...007. Revenue for the six months ended June,30, 200...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5
...h regulators, gave their nod to the first new drug...heart transplant patients.// The drug, Astellas Ph... rejection of liver and kidney transplants. Dr. S... Center for Drug Evaluation and Research said, "Th...
...dia’s population stabilization solely rests on the... which has the highest fertility rates. 'India's p...ttar Pradesh take an immediate lead in checking po...ecutive director, Population Foundation of India, ...
...rther six months of patent extension by the FDA fo...n//, Provigil. Cephlaon had complied with the te...he provision of clinical studies data after studyi...on pediatric patients. Cephalon has settled the ‘...
...ncreased risk of heart attack associated with Viox...views are 'out of the mainstream' as it is based o...Merck and Co. Thomas Cona and John Mcdarby have s...g that use of the drug had resulted in heart attac...
Other Medicine News:Health News:Doctor Grilled In Court For False Report About Vioxx Health Risk 2
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: